Alnylam, Tekmira Form New RNAi Drug-Delivery Collaboration
August 06, 2009
Alnylam, Tekmira Form New RNAi Drug-Delivery Collaboration
Alnylam will have the exclusive rights to all new inventions resulting from the alliance, as well as the rights to sublicense any related intellectual property. Tekmira will have the right to use new inventions with its own RNAi therapeutics.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Tekmira Says USPTO Declares Interference for Alnylam Patent as Firms Continue Litigation
October 20, 2011 / Gene Silencing News - AlCana Denies Breaking Non-Compete Pact as Tekmira Decries Deception in Ongoing Lawsuit
August 18, 2011 / Gene Silencing News - Tekmira Amends Alnylam Lawsuit to Include AlCana Technologies
June 9, 2011 / Gene Silencing News - Alnylam Extends Research Deal with UBC, AlCana
April 7, 2011 / Gene Silencing News - Amid Advances in Lipid-Based Delivery, Some See Other Technologies Being Passed Over
January 13, 2011 / Gene Silencing News